Skin Sensitization Test: Scientifically Assessing the Risk of Allergic Contact Dermatitis

Allergic contact dermatitis is an immune-mediated, delayed-type hypersensitivity reaction that develops in response to chemicals and medical devices. This condition, whose prevalence in the general population is steadily increasing, can result from occupational exposure or contact with consumer products and medical devices. Determining a substance’s potential for skin sensitization (allergy-inducing) is a key step in the safety assessment of chemicals, cosmetic ingredients, pesticides, biocidal products, and medical devices. Skin sensitization testing forms the scientific basis of this assessment. Our laboratory conducts skin sensitization tests in accordance with OECD and ISO standards, under GLP principles, and with full adherence to the 3R approach.

The Scientific Basis and Importance of Skin Sensitization

Sensitization differs fundamentally from other types of local toxicity because this reaction is characterized by a dose-response relationship and immune memory. Once sensitized, an individual may develop a severe reaction even upon re-exposure to very low concentrations. Therefore, a substance with sensitization potential can pose a serious public health risk even if it does not exhibit acute toxicity. Allergic contact dermatitis manifests as itching, redness, blistering, peeling, and, in chronic cases, lichenification (thickening of the skin). Cases resulting from occupational exposure can lead to lost work time and a reduced quality of life.

The sensitization process occurs in two stages. The first stage, the induction (sensitization) phase, begins when a substance penetrates the skin and interacts with immune system cells. In this stage, the substance binds to a carrier protein to form a hapten-protein complex, which is then transported to the lymph nodes by Langerhans cells. In the lymph nodes, T lymphocytes are activated, and substance-specific memory cells are formed. This process typically lasts 10–15 days and does not produce any clinical symptoms. The second stage, the elicitation (provocation) phase, occurs when the sensitized individual is re-exposed to the same substance. This time, memory T lymphocytes are rapidly activated, and an inflammatory reaction develops within 24–72 hours. For this reason, both the induction and elicitation phases must be evaluated in sensitization tests.

Skin sensitization data are directly used to determine the hazard statements and pictograms used in product labeling, to prepare safety data sheets (SDS), to define occupational exposure limits, and to formulate recommendations for personal protective equipment. Furthermore, these data are a mandatory requirement for regulatory submissions for cosmetic products, cleaning agents, and medical devices.

OECD TG 406: Traditional In Vivo Sensitization Tests

OECD TG 406 is a classic in vivo test guideline used to assess the skin sensitization potential of chemical substances. Two different methods are defined within this guideline: the Guinea Pig Maximization Test (GPMT) and the Buehler Test. Both methods use the guinea pig model, and the basic principle involves evaluating the allergic response through a challenge (provocation) application a specific time after the induction phase with the test substance.

The GPMT (Guinea Pig Maximization Test) is a highly sensitive method that enhances the immune system using an adjuvant (Freund’s Complete Adjuvant – FCA), thereby enabling the detection of even substances with low sensitization potential. Induction is achieved through a combination of intradermal injection and topical application. The use of an adjuvant enhances the immune response, enabling the detection of even weak sensitizers. For this reason, the GPMT is preferred for the evaluation of industrial chemicals, pesticides, and low-potential sensitizers.

The Buehler Test, on the other hand, does not use an adjuvant; induction is achieved solely through topical application. Consequently, the Buehler Test models human exposure scenarios more realistically but has lower sensitivity compared to GPMT. While the Buehler Test is preferred for topical medications and cosmetic ingredients, the GPMT is more suitable for industrial chemicals and pesticides. In both methods, evaluation is performed by grading skin reactions (erythema and edema) at 24 and 48 hours after the challenge.

OECD TG 429: Local Lymph Node Assay (LLNA) – A Modern and Quantitative Approach

OECD TG 429 is a modern alternative using a mouse model that offers significant advantages over guinea pig tests in the assessment of skin sensitization. The Local Lymph Node Assay (LLNA) is the first validated in vivo method that measures the induction phase of sensitization and expresses the results quantitatively. The basic principle of the test involves the topical application of the test substance to mouse ear skin, followed by the measurement of lymphocyte proliferation in regional (auricular) lymph nodes using radioactively labeled thymidine.

The most significant advantages of the LLNA compared to the GPMT and Buehler methods are as follows: It provides quantitative results; the sensitization potential is expressed numerically by calculating the Stimulation Index (SI). The EC3 value can be calculated; this value indicates the effective concentration at which the test substance causes stimulation at a rate of three percent and allows for a comparative grading of sensitization potential. It requires fewer animals and a shorter duration; while the GPMT requires 20–30 guinea pigs and 4–6 weeks, the LLNA requires only 16–20 mice and 1–2 weeks. It is 3R-compliant; the LLNA better aligns with the principles of Reduction (fewer animals) and Refinement (less invasive procedures). It provides an objective assessment; since it is based on radioactivity measurement rather than visual scoring, subjective judgments are minimized.

The OECD currently recommends the LLNA (TG 429) as the primary method for assessing skin sensitization to chemical substances; it positions guinea pig tests (TG 406) as a backup method only for specific cases where the LLNA cannot be applied.

ISO 10993-10: Evaluation of Skin Sensitization for Medical Devices

ISO 10993-10 is the international standard defining skin sensitization tests within the scope of biocompatibility assessment for medical devices. This standard includ es test methods that use extracts obtained from the device or the device material itself to evaluate the potential for allergic contact dermatitis posed by medical devices and biomaterials. Under ISO 10993-10, three primary methods are recommended for skin sensitization assessment: GPMT, the Buehler Test, and LLNA. The standard states that, based on chemical characterization data and existing literature, sensitization assessment can be completed without animal testing in certain cases.

The most significant difference between ISO 10993-10 and previous versions is its adoption of a risk-based approach to test method selection and its reference to the use of in vitro/in chemico alternative methods. The standard mandates a sensitization assessment for all medical devices that come into contact with the skin; however, the scope and method of the test are determined based on the duration and type of contact.

The table below summarizes the key guidelines used in skin sensitization assessment and their characteristics.

Modern Alternatives: In Vitro and In Chemico Methods

Today, there are in vitro and in chemico methods—developed as alternatives to animal testing for skin sensitization assessment and validated by the OECD—that are increasingly preferred because they comply with the 3R principles and provide faster, more economical, and more reproducible results.

OECD TG 442C (DPRA – Direct Peptide Reactivity Assay) is an in chemico test that evaluates protein binding (haptenation), the first key step in sensitization. It measures the test substance’s potential to react with synthetic peptides. OECD TG 442D (KeratinoSens™ / ARE-Nrf2 Luciferase Assay) is an in vitro test that evaluates keratinocyte activation; it uses a human keratinocyte cell line. OECD TG 442E (h-CLAT / U-SENS™ / IL-8 Luc Test) is an in vitro test that evaluates dendritic cell activation; human monocyte/dendritic cell-like cell lines are used.

Since these alternative methods can only assess a single stage of sensitization on their own, they provide the highest accuracy when used in combination within the framework of the OECD’s Defined Approach (DA). Since animal testing is banned in the EU, particularly for cosmetic products, these in vitro/in chemico methods are the only mandatory option. By applying these modern alternatives, our laboratory is able to provide sensitization assessments for cosmetic and personal care products entirely without the use of animals.

GHS Classification and Skin Sensitization Categories

Skin sensitization test results are classified into two main categories according to the criteria of the Globally Harmonized System (GHS). Category 1 (Skin Sensitization) indicates that a substance has the potential to cause an allergic response following skin contact. This category is labeled with the statement “May cause an allergic skin reaction” and is marked with the exclamation mark pictogram (GHS07). Subcategory 1A (Strong Sensitizer) covers substances that cause reactions with high frequency and severity; subcategory 1B (Weak/Moderate Sensitizer) covers substances that cause reactions with lower frequency. These subcategories are particularly important in determining risk management measures.

Unclassified substances, on the other hand, are those that do not demonstrate skin sensitization potential based on available data. This classification is directly used to determine numerous regulatory requirements, ranging from product labeling to transportation, storage, and usage instructions. Incorrect or incomplete classification can lead to both legal penalties and compromised user safety.

Conducting Skin Sensitization Tests in Our Laboratory

In our GLP- and GMP-certified laboratory, we conduct skin sensitization tests in full compliance with international standards. Our experienced team of toxicologists and veterinary pathologists evaluates your product’s physicochemical properties, chemical structure, and regulatory requirements before each study to recommend the most appropriate testing strategy. We have the infrastructure for radioactive labeling for the LLNA and fully implement the GPMT and Buehler tests.

For medical devices, in accordance with ISO 10993-10:2021, testing is performed using extracts prepared from your device in compliance with ISO 10993-12, and the results are integrated into your biocompatibility assessment dossier. Furthermore, by offering in vitro/in chemico alternatives that do not require the use of animals, we demonstrate the utmost commitment to the 3R principles.

One of our laboratory’s key advantages is the ability to directly integrate test results into your regulatory submissions. Full study reports compliant with the OECD template meet the requirements of EU REACH, the CLP Regulation, U.S. EPA FIFRA, TSCA, EU MDR (2017/745), and Turkey’s KKDIK. Furthermore, we provide all necessary data in full for the preparation of your product’s Safety Data Sheet (SDS).

Frequently Asked Questions

One of the most common questions we receive regarding skin sensitization testing is whether LLNA can replace GPMT and the Buehler test in all cases. In most cases, yes; the OECD recommends the LLNA as the primary method and positions guinea pig tests only as a backup for situations where the LLNA cannot be applied. However, some regulatory authorities may require the GPMT for specific product types.

We are also frequently asked which sensitization test is mandatory for cosmetic products. According to the EU Cosmetics Regulation (EC 1223/2009), animal testing for cosmetic products and their ingredients is completely prohibited. Therefore, the use of in vitro/in chemico methods covered by OECD TG 442C, 442D, and 442E, in conjunction with the Defined Approach (DA), is mandatory.

Regarding the circumstances under which a sensitization test is mandatory for medical devices, the answer is that, in accordance with ISO 10993-1, a sensitization assessment is required for all medical devices that come into contact with the skin. Under the EU MDR (2017/745), this data is required in the biocompatibility dossier depending on the device class and duration of contact. Regarding the test duration, the LLNA takes 3–4 weeks, the GPMT/Buehler test takes 6–8 weeks, and the in vitro alternatives take 2–3 weeks. The total duration may vary depending on the intensity of the study and the quality assurance review.

Skin sensitization is a toxicological endpoint that directly affects user safety and cannot be overlooked. Accurately determining the risk of allergic reactions using scientific methods is a critical factor in establishing your product’s reliability and market acceptance. Our laboratory offers all skin sensitization tests covered by OECD TG 406, OECD TG 429, and ISO 10993-10 in accordance with GLP standards and with the utmost commitment to the 3R principles. To work with us on planning the most appropriate sensitization assessment strategy for your chemical substance or medical device, contact us.